FDA OKs first generic version of Trileptal

Oct 10, 2007

The U.S. Food and Drug Administration announced approval of the first generic versions of the anti-convulsion drug Trileptal (oxcarbazepine).

The FDA said it approved generic oxcarbazepine for use alone or in combination with other medications in the treatment of partial seizures in adults and children aged 4 years and older.

Oxcarbazepine tablets in three strengths (150 milligrams, 300 milligrams and 600 milligrams) are manufactured by Roxane Laboratories Inc., Glenmark Pharmaceuticals Ltd. and Sun Pharmaceutical Industries Ltd.

According to the publication Drug Topics, Trileptal was the 74th best selling brand-name drug by retail dollars in the United States last year.

Copyright 2007 by United Press International

Explore further: FDA warns of compounded drug recall by Texas firm

add to favorites email to friend print save as pdf

Related Stories

Social Security spent $300M on 'IT boondoggle'

10 hours ago

(AP)—Six years ago the Social Security Administration embarked on an aggressive plan to replace outdated computer systems overwhelmed by a growing flood of disability claims.

Cheaper wireless plans cut into AT&T 2Q profit

10 hours ago

(AP)—AT&T posted lower net income for the latest quarter due to cheaper cellphone plans it introduced as a response to aggressive pricing from smaller competitor T-Mobile US.

Awarded a Pell Grant? Better double-check

10 hours ago

(AP)—Potentially tens of thousands of students awarded a Pell Grant or other need-based federal aid for the coming school year could find it taken away because of a mistake in filling out the form.

Recommended for you

Journal raises concern about blood-thinning drug

11 hours ago

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

User comments : 0